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Suppressor of cytokine signalling 3 is an important protein in the maintenance and 
homeostasis of the intestinal epithelium. Its dysregulation is associated with severe disease 
including inflammatory bowel disease and colorectal cancer. It is therefore a tightly regulated 
protein, its oscillatory nature thought to be regulated by both transcriptional and post-
translational mechanisms such as proteasomal degradation and autophagy. The intestinal 
microbiota has been implicated in intestinal inflammation, inflammatory bowel disease and 
inflammation-associated cancer. We used two models of dysbiosis in both human resection 
specimens and cultured human intestinal epithelial cells. Both models are used to investigate 
the impact of dysbiosis on inflammatory signalling pathways and autophagy. In addition, we 
used transgenic cells to investigate the impact of SOCS3 expression upon these pathways. Our 
results suggest that dysbiosis may stimulate autophagy, but not chronic inflammation. 
Meanwhile, SOCS3 modulation did not impact inflammatory signalling pathways, but may be 
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1.1. Colorectal Cancer 
In 2018, around 18 million cancer diagnoses were made worldwide. Of these new cases, 
almost 2 million were colorectal cancer (CRC), making it the third most common cancer 
worldwide in both men and women (Table 1.1) (World Health Organization, 2018).  
Cancer Number of diagnoses % of all new cases Crude rate per 100,000 
All cancers 18 078 957  N/A 236.9 
Lung 2 093 876 11.58 27.4 
Breast 2 088 849 11.55 55.2 
Colorectum 1 849 518 10.23 24.2 
Prostate 1 276 106 7.06 33.1 
Stomach 1 033 701 5.72 13.5 
Liver 841 080 4.65 11 
 
Table 1.1. Newly diagnosed cancer cases in 2018, ranked by incidence. Of 17,036,901 newly diagnosed 
cases, over 10% (1,849518 cases) were colorectal cancer. Colorectal cancer incidence was preceded only by 
lung and breast cancer, which accounted for 2,093,876 and 2,088,849 cases (or around 12% each), respectively. 
Data from WHO (World Health Organization, 2018) 
 
 
Mirroring the global patterns of cancer incidence, colorectal cancer was the 3rd most 
common cancer in men and women in the UK in 2016 (Figure 1.1) and is currently the second 
most common cancer death worldwide (Cancer research UK, 2019). Of the 9.6 million cancer 
deaths reported in 2018, colorectal cancer was responsible for 862,000 deaths, second only to 
lung cancer, which caused 1,760,000 deaths (World Health Organization, 2018). Five-year 
survival rates suggest that earlier diagnoses of CRC are critical to reducing mortality and 
promise a better prognosis for many sufferers (World Cancer Research Fund and American 
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institute for cancer research, 2017). In fact, 5-year survival rates surge from just 13% in late-
stage diagnoses to 90% in early-stage diagnoses – an increase just short of 600%.    
 
 
1.1.1. Aetiology  
Lifestyle and environmental factors weigh heavily on the aetiology of colorectal cancer. 
For instance, sub-populations living within the same community are subject to different degrees 
of risk of developing CRC, despite being exposed to comparable environmental factors (Boyle 
and Langman, 2000). On the other hand, studies have demonstrated that, as well as dissociating 
from the CRC risk patterns associated with their home country, groups of migrants quickly 
adopt those associated with host countries, demonstrating a strong environmental influence on 
risk factors (Boyle and Langman, 2000). Specifically, data has shown CRC incidence increased 
Figure 1.1. Most common cancers amongst UK men and women in 2016. Colorectal cancer is the third 
most common cancer in both men and women in the UK. In men, colorectal cancer incidence is preceded just 
prostate and lung cancer, accounting for 13% of male cancer cases in the UK. In women, colorectal cancer 
incidence is preceded by just breast and lung, accounting for 10% of female cancer cases in the UK. Figure 
from (Cancer research UK, 2019) 
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by as much as four-fold in Japanese populations who migrated to the USA, relative to control 
populations who remained in Japan. Furthermore, this increase saw the incidence amongst 
migratory Japanese populations roughly match the incidence seen in the host country (Boyle 
and Langman, 2000). Such findings have branded CRC an ‘environmental’ disease – 70-80% 
of colorectal cancer cases may be attributed to cultural, social and lifestyle practices, with 
genetic factors being far less influential than in many other cancers (Boyle and Langman, 
2000). As well as this, CRC is viewed as a disease of the westernised and developed world, 
although its prevalence is rising in economically developing countries (Bishehsari et al., 2014).  
Arguably the most potent environmental factor influencing CRC is diet and nutrition. 
In 1990, Willett et al observed a strong and significant positive correlation between animal fat 
consumption by women and colon cancer risk, demonstrating that the relative risk to women 
who reported eating red meat at least once per day was 2.49 times that to women who consumed 
red meat less than once per month (Willett et al., 1990). Meanwhile, the relative risk of 
developing CRC is negatively correlated with physical activity. A major study illustrating this 
association measured the physical activity of 100 recently diagnosed CRC patients in Iran and 
compared it with that of unaffected companions who were not first or second-degree relatives. 
Occupational physical activity, household physical activity, and leisure activity were measured 
using a questionnaire. The results demonstrated that whilst there was no significant difference 
in occupational or household physical activity between the female case and control groups, 
there were statistically significant differences in levels of leisure activity between the two 
groups. The group concluded that risk of developing CRC is significantly reduced by moderate 




The impact of diet and nutrition on CRC risk extends far beyond simple correlations. 
Diet directly impacts nuclear receptor function as well as the intestinal microbiota, the pro-
inflammatory capacities of which can be exacerbated by diet. Specifically, diets high in animal 
products and deficient in complex carbohydrates have been reported as major offenders 
(Bishehsari et al., 2014, Greer and O'Keefe, 2011). Nuclear receptors facilitate responses to 
environmental alterations by binding compounds from the diet and activating the appropriate 
metabolic pathways (Francis et al., 2003). It is now understood that nuclear receptors play key 
roles in both cancer development and progression (Dhiman et al., 2018). The involvement of 
the nuclear hormone receptor peroxisome proliferator‑activated receptor delta (PPARδ) in the 
development and progression of CRC was long hypothesized after Park et al demonstrated that 
generation and inoculation of a PPARδ null cell line (simulating disruption of both alleles) in 
murine models inhibited the tumorigenic potential of affected cells (Park et al., 2001). Today, 
it is understood that although PPARδ is normally expressed by epithelial cells of the colon, it 
is upregulated in the vast majority of human colorectal carcinomas (Gupta et al., 2000, 
Takayama et al., 2006). Furthermore, its upregulation is most notable in malignant cells, 
demonstrating a role of PPARδ in both the development and progression of CRC (Takayama 
et al., 2006). 
 
1.1.2. Diagnosis  
 First-line screening methods for CRC are stool-based and detect the presence of blood 
in patient faecal samples. The tests are readily available in two forms: the guaiac faecal occult 
blood test (g-FOBT) and the faecal immunochemical test (FIT).  
 There are numerous studies backing the use of g-FOBT in the reduction of CRC 
mortality. Annual g-FOBT screening is associated with a 33% decrease in 13-year cumulative 
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mortality, and even less frequent biennial screening still reduces mortality by 18% (Mandel et 
al., 1993, Kronborg et al., 1996). In addition to the abundant evidence rationalising the use of 
g-FOBT for first-line CRC screening, there are a number of advantages which make it an 
appealing strategy. Not only does the non-invasive nature of the procedure make g-FOBT a 
popular option amongst patients, but its cost effectiveness and high specificity make it equally 
favourable among healthcare professionals as well (Hassan et al., 2012, Mousavinezhad et al., 
2016, Dancourt et al., 2008). Of course, g-FOBT is not without its drawbacks, the most notable 
being its low sensitivity which makes it susceptible to producing false positive results. 
Although such results are often due to the detection of non-human blood from the patient’s 
diet, studies implementing dietary restrictions to negate the effect of animal haem found that 
the rates of false positives were not significantly reduced by such efforts (Schreuders et al., 
2016, Coughlin and Friend, 1987, Pignone et al., 2001). In fact, the restrictions were associated 
with lower patient adherence, which is essential for effective testing (Konrad, 2010). 
The FIT method possesses a similarly impressive specificity to g-FOBT but boasts a 
higher sensitivity due to the use of antibodies which selectively bind human haemoglobin 
(Allison et al., 1996). Despite this, the efficacy of FIT in reducing CRC incidence and mortality 
relative to gFOBT is poorly studied, meaning the data to support its preferential use is still 
perhaps insufficient. However, its improved sensitivity and patient compliance often brand FIT 
the superior first-line screening test (Parra-Blanco et al., 2010).  
Although g-FOBT and FIT are undoubtedly useful tools, their low capacity for the 
detection of premalignant lesions means that screening must be conducted biennially or ideally 
annually to effectively reduce CRC mortality (Hassan et al., 2012). Should a g-FOBT or FIT 
return a positive result, then patients are referred for a colonoscopy or flexible sigmoidoscopy 
(FS). These screening methods can detect pre-malignant lesions but are highly invasive and so 
not used without sufficient concern. The ability to screen the colon in its entirety means that 
6 
 
colonoscopy is widely regarded as the most effective CRC screening method, whilst FS is able 
to examine just the rectum and sigmoid colon (Bénard et al., 2018). In spite of this, FS is often 
favoured due to its less-invasive nature and proven effectiveness; in one study FS alone reduced 



















1.2. Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is characterised by non-infectious, recurring 
inflammation of the gastrointestinal tract and affects almost 7 million people worldwide 
(Inflammatory Bowel Disease Collaborators, 2019). The term IBD is used to describe multiple 
idiopathic diseases, but Ulcerative Colitis (Wilks 1859) and Crohn’s Disease (Crohn et al., 
1952) are most prominent. Ulcerative Colitis (UC) describes inflammation specific to the 
colonic mucosa, whilst Crohn’s Disease (CD) refers to inflammation within any region of the 
gastrointestinal tract and throughout the wall (Xavier and Podolsky, 2007). Despite striking 
similarities in their symptoms, contributing factors and treatments, the extent to which these 
diseases are related is still up for debate, with much of this uncertainty on account of an 
incomplete understanding of the aetiology. What is understood is that IBD most often arises 
due to an immune response to the intestinal microbiota in a genetically predisposed individual.  
 
1.2.1. Genetics  
Family history is a major risk factor associated with IBD pathogenesis. First degree 
relatives of UC and CD patients are 10-fold more likely to develop the same disease themselves 
than first-degree relatives of unaffected controls. Furthermore, the risk to second-degree 
relatives of affected individuals is also increased (Orholm et al., 1991). In 2001, the first 
susceptibility gene for CD was identified by two separate research groups (Ogura et al., 2001, 
Hugot et al., 2001). Three polymorphisms at the carboxy terminal end of the nucleotide-binding 
oligomerization domain containing 2 (NOD2) gene are all linked with CD (Hugot et al., 2001).  
More recently, a meta-analysis of genome wide association studies (GWAS) of IBD identified 
163 loci which were significantly associated with the disease. Of these loci, 110 are common 
to CD and UC, 30 are CD-specific and 23 are UC-specific (Jostins et al., 2012).  
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1.2.2. The Intestinal Microbiota  
The gut microbiota is a population of tens to hundreds of trillions (1013 – 1014) of 
symbionts residing in the within the gastrointestinal (GI) tract (Bishehsari et al., 2014). Their 
existence there is vital to numerous physiological processes including inflammation, intestinal 
and immune homeostasis, response to pathogens, and digestion (Halfvarson et al., 2017, 
Rakoff-Nahoum et al., 2004, Hooper et al., 2003, Lathrop et al., 2011, Tancrède, 1992, Gill et 
al., 2006).  
The role of the microbiota in the development of IBD is a topic of great interest and 
murine studies have been indispensable in our current understanding of this relationship. For 
instance, an earlier study found that without the presence of resident gut bacteria, colitis cannot 
develop (Veltkamp et al., 2001). More recently, germ-free mice inoculated with the microbiota 
of IBD models had higher T helper cell counts, and lower regulatory T cell (Treg) counts than 
germ-free mice inoculated with healthy microbiotas (Britton et al., 2019). Furthermore, 
introduction of T cells to B and T lymphocyte-deficient mice induced IBD (Powrie et al., 1994). 
The healthy microbiota was therefore associated with a higher degree of immune tolerance, 
whilst the microbiota of IBD models is associated with a heightened immune response. In 
addition, a less diverse microbiome is associated with increased risk of IBD (Glassner et al., 
2020). 
Numerous studies in both animals and humans have demonstrated that the diversity of 
the microbiota is influenced by the host diet. Food quality, incorporation of both plant and 
animal products, as well as fat and fibre consumption have all been closely linked with 
microbiome diversity (Yu et al., 2021, Lau et al., 2018, Hildebrandt et al., 2009, Menni et al., 
2017). Furthermore, nutrient deprivation in the intestinal lumen causes dysbiosis and, on 
account of the capacity of the microbiota to modulate intestinal inflammation, this may be 
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detrimental to the regulation of signalling pathways in the intestinal epithelium (Beamish et 
al., 2017, Yang et al., 2017, Buttó et al., 2015). Our understanding of the gut microbiota was 
long limited to its bacterial constituents, but more recently our comprehension of their viral 
cohabitants has advanced.  
The virome is composed of both prokaryotic and eukaryotic viruses, which interact with 
both resident bacteria and host cells, respectively. Given the requirement for phages to infect 
bacteria, there is a well-established positive correlation between the diversity of these two 
populations (Breitbart et al., 2003). Numerous studies have now reported alterations in the 
intestinal viromes of individuals affected by a range of diseases, indicating a compelling link 
between the presence of exogenous DNA and modulation of the gut microbiome. Specifically, 
the abundance of Caudovirales increased significantly in the intestines of patients with 
ulcerative colitis and Crohn’s disease (Norman et al., 2015), whilst virome has been found to 












1.3. The Intestine  
 The human intestine is lined with villi which protrude into the lumen and aid digestion. 
Mechanical abrasion caused by movement of food through the intestine means that the 
epithelium must be turned over every 3 to 5 days (Karam, 1999). Around 107 colonic crypts 
known as the crypts of Lieberkühn are dedicated to maintaining the intestinal epithelium 
(Stamp et al., 2018). Each crypt is composed of approximately 2000 cells, around 100 of which 
are stem cells residing in the stem cell niche at the crypt base (Kang and Shibata, 2013) (Figure 
1.2).  The intestinal epithelium is made up of 6 mature cell types, which can be sub-divided 
into 2 categories: absorptive cells and secretory cells. Absorptive cells include enterocytes and 
M cells, whilst secretory cells include Paneth cells, goblet cells, enteroendocrine cells and tuft 
cells (Gehart and Clevers, 2019). High intestinal epithelial turnover drove the evolution of a 
complex system devoted to supplying the intestinal epithelium with new cells in specific 
quantities.  
Figure 1.2. Organisation of the intestinal epithelium.  Each villus is surrounded by crypts, at 
the base of which stem cell pools constantly renew the epithelium as old cells subject to abrasion 
are sloughed off into the lumen. Figure from (Gehart and Clevers, 2019) 
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1.3.1. Intestinal Stem Cells   
The constant requirement for intestinal epithelial replenishment is met by intestinal 
stem cells (ISCs) which divide asymmetrically to give rise to non-identical stem cell and 
progenitor cell daughters. Whilst stem cells remain in the niche, progenitor cells undergo 
around 5 divisions, during which they differentiate and migrate upwards (Cui and Chang, 
2016). Eventually, mature cells reach the intestinal epithelium at the top of the crypt. After just 
3-5 days they are shed into the lumen and must be replaced by new cells from the niche (Gehart 
and Clevers, 2019).  There are thought to be 2 stem cell populations within the intestine: Crypt 
base columnar cells and +4 cells. 
 
1.3.2. Crypt Base Columnar Cells  
Crypt base columnar (CBC) cells were the first intestinal stem cells to be characterised, 
after Cheng and Leblond recognised that enteroendocrine cells were terminally differentiated 
yet phenotypically similar to CBC cells. They therefore proposed that CBC cells were the 
predecessors of enteroendocrine cells (Cheng and Leblond, 1974). Bjerknes and Cheng later 
identified short-lived and long-lived clones in the intestinal epithelium. The short-lived clones 
are now known as short-lived progenitor cells, whilst the long-lived clones may be categorised 
as long-lived progenitor cells or stem cells (Bjerknes and Cheng, 1999). Short-lived progenitor 
cells comprise lineage restricted columnar and mucous progenitors, as well mix progenitors 
which can differentiate into both columnar and mucous short-lived progenitors. Long-lived 
progenitor cells comprise pluripotent stem cells, long-lived mucous progenitors and long-lived 
columnar progenitors. Pluripotent stem cells give rise to mix short-lived progenitor cells, 
mucous long-lived progenitor cells and columnar long-lived progenitor cells. These in turn give 
rise to mucous and columnar short-lived progenitor cells which, when matured to post-mitotic 
12 
 
columnar and mucous cells, function in the intestinal epithelium. (Figure 1.3). Long-lived 
progenitors remain at the base of the crypt, whilst short-lived progenitors divide 2-3 times, 
migrate upwards and differentiate to form a post-mitotic cell (Bjerknes and Cheng, 1999).  
CBC cells express the Wnt target gene Leucine-rice repeat-containing G protein-
coupled receptor 5 (Lgr5) and are the only cell in the colon to do so (Barker et al., 2007). Since 
the identification of Lgr5 as an intestinal stem cell marker, it has been identified as a marker 
for adult stem cell populations in numerous other tissues, including the hair follicles, stomach 
and kidneys (Jaks et al., 2008, Barker et al., 2010, Barker et al., 2012). Furthermore, lineage 
tracing using an inducible Cre knock-in allele and the Rosa26-lacZ reporter revealed that the 
CBC cell is responsible for the production of all intestinal epithelial lineages. Lgr5 positive 
Figure 1.3. The maturation of pluripotent CBC cells to form mature post-mitotic columnar and 
mucous cells. Pluripotent stem cells (S) divide asymmetrically to produce an identical stem cell (S) and 
either a short-lived mix progenitor (Mix), a long-lived columnar progenitor (C0), or a long-lived mucous 
progenitor (M0). Short-lived mix progenitor cells give rise to short-lived columnar (C1) or mucous (M1) 
cells, meanwhile long-lived progenitor cells divide asymmetrically to produce an identical long-lived 
progenitor cell (C0 or M0) and a short-lived progenitor of the same lineage (C1 or M1). Figure from 
(Bjerknes and Cheng 1999)  
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(Lgr5+) CBC cells give rise to enterocytes, M cells, goblet cells, Paneth cells and tuft cells, as 
well as the previously proposed enteroendocrine cells (Barker et al., 2007). 
 
1.3.3. +4 Cells  
The +4 cell, named for its position in the crypt, is now recognised as a second intestinal 
stem cell. However, this concept was challenged for some time due to characteristics which 
brought the nature of these cells into question. Their label-retaining ability made +4 cells viable 
stem cell candidates and a number of studies identified a range of genetic markers for them. 
These include doublecortin-like kinase 1 (DCAMKL1), secreted Frizzled-related protein 5 
(FRP-5) and B lymphoma Mo-MLV insertion region 1 (Bmi1) (Giannakis et al., 2006, 
Gregorieff et al., 2005, Sangiorgi and Capecchi, 2008). Bmi1 is perhaps the most widely 
recognised for this lineage; expressing cells were found to be capable of restoring the intestinal 
epithelium single-handedly, but they differed greatly in function and characteristics from Lgr5+ 
CBC cells. Upon their initial characterisation, the stem cells of the intestine were each 
designated a rank within a hierarchy (Potten, 1998). Ancestor stem cells (now recognised as 
mitotically active CBC cells) are primarily responsible for intestinal epithelial regeneration and 
sit at the bottom of the hierarchy due to their vulnerability to irradiation. In the event that this 
population is eradicated, reserve stem cells (now recognised as quiescent Bmi1+ +4 cells) 
repopulate the crypts due to their higher resilience to such insult (Yan et al., 2012). +4 cells are 
therefore regarded as a reserve stem cell population which serves primarily to replenish 






1.3.4. Intestinal Stem Cells and Cancer  
The high abundance and proliferation rate of cells in the small intestine relative to the 
large should make it an obvious area of concern with regards to cancer predisposition. 
Remarkably, cancer of the small bowel is very rare. Between 2015 and 2017, 1,703 new cases 
were reported in the United Kingdom and these comprised below 1% of the total number of 
cancer cases reported in that time (Cancer Research UK, 2020). The reasons for this lie in the 
stem cell populations of the small and large intestine.  
Apoptosis can occasionally be observed at the stem cell position in the healthy human 
small intestine, meanwhile it is almost inexistent in the large intestine. Furthermore, when 
apoptosis does occur in the large intestine, it can be seen throughout and is not limited to the 
stem cell position (Potten, 1998). Upon exposure to identical doses of radiation, cells of the 
small intestine undergo apoptosis at a higher rate than those of the colon. Furthermore, 
following irradiation, expression of the tumour suppressor gene p53 by stem cells of the small 
intestine was high but remained low throughout the colon. Damage-induced apoptosis in the 
small intestine ceased upon p53 knockout in mouse models (Merritt et al., 1994). This was an 
early indication that p53 was involved in destroying damaged cells and circumventing 
neoplasia. Further investigation confirmed this and revealing that mutations in p53 are common 
in colorectal carcinoma (Potten, 1998).  
 The differences in cancer incidence throughout the intestine cannot be solely attributed 
to expression of a tumour suppressor gene in the small bowel; the anti-apoptotic gene bcl-2 is 
expressed exclusively in the large intestine, meaning that cells undergoing neoplastic 
transformation often will not be killed (Merritt et al., 1995). Furthermore, reciprocal expression 
of bcl-2 and p53 by carcinomas only widens the gap between the small and large intestine’s 
vulnerability to cancer development.  
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1.3.5. Regulation of Intestinal Stem Cell Populations  
The process of self-renewal for +4 and CBC cells in the intestinal crypt is highly 
dependent on signal transducer and activator of transcription 3 (STAT3) signalling (see 1.4.4). 
Studies which inactivated floxed STAT3 (STAT3fl) alleles reported apoptosis and complete 
eradication of STAT3fl/- cells from murine crypts, followed by replenishment of normal 
intestinal epithelial cell (IEC) pools (Matthews et al., 2011). As well as supporting ISC turnover 
under normal homeostatic conditions, STAT3 also stimulates proliferation in surviving cells 
following physical insult to the intestinal epithelium. Although this role has implicated STAT3 
in tumourigenesis, organoid studies found that without STAT3 activation, insufficient 
interleukin-2 (IL-2) signals prevented organoids from maturing (Oshima et al., 2019, Jung et 
al., 2019).  
In 2011, Takeda et al identified the homeodomain-only protein homeobox (HOPX) as 
a +4 cell marker. This novel gene is expressed specifically by +4 cells capable of generating 
CBC cells, and +4 cells generated from CBCs. This alluded to an unprecedented capability of 
+4 and CBC cells to ‘convert’ between lineages and facilitate regeneration of the intestinal 
epithelium regardless of the environment, which may favour one population (Takeda et al., 
1998). 
In a 2012 study which set out to deduce the molecular signature of the CBC cell, Javier 
Munoz and his colleagues observed the expression of +4 cell markers including HOPX, Bmi1, 
Tert, and Lrig1 by CBC cells (Muñoz et al., 2012). A later study led by Tara Srinivasan in 2016 
went on to find that the key pathway underlying stem cell regulation by interconversion was 
the Notch signalling pathway. Murine organoids and pair cell assays were used to demonstrate 
that intestinal stem cells could divide both symmetrically and asymmetrically, to produce 
identical daughter pairs (Bmi+/Bmi+ or Lgr5+/Lgr5+ pairs) and non-identical Bmi+/Lgr5+ 
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daughter pairs, respectively. Furthermore, the rate of asymmetric divisions fluctuated in 
accordance with Notch signalling levels, which occur in response to microenvironmental 
changes in the intestine. Whilst asymmetric divisions increased following activation of Notch 
signalling, Notch inhibition reduced asymmetric division frequency (Srinivasan et al., 2016). 
Tumour Necrosis Factor alpha (TNF-α) was used to stress organoid cells and caused an 
increased rate of asymmetric divisions. Addition of the γ-secretase inhibitor DAPT inhibited 
Notch signalling, resulting in the formation of more Bmi+/Bmi+ and Lgr5+/Lgr5+ pairs, relative 
to non-identical daughter pairs. The response of intestinal stem cells to similar stresses was 
tested in vivo by treating mice with dextran sulphate sodium (DSS) to induce intestinal 
inflammation. As expected, an increased rate of asymmetric divisions was observed, which fell 
again upon subsequent treatment with DAPT. However, it must be noted that although Notch-
dependent asymmetric division was observed both in vitro and ex vivo, it was not so often the 
case in vivo. Regardless, the results demonstrated that intestinal inflammation induces Notch-
dependent asymmetric division in ISCs in order to efficiently replenish both stem cell reserves 











1.4. Cell Signalling in the Intestinal Epithelium  
 
1.4.1. Cytokines 
The cytokine protein superfamily plays a fundamental role in our innate immune system 
and intestinal epithelial barrier maintenance (Holdsworth and Gan, 2015). These small peptides 
are secreted most readily by immune cells and interact with membrane-bound receptors of the 
same cell, nearby cells or distant cells. The result is the initiation of autocrine, paracrine or 
endocrine responses which allow the host immune system to respond to stimuli such as 
infection and trauma (Zhang and An, 2007, Dinarello, 2000).  The responses triggered by 
cytokine signalling are extensive but ultimately culminate in regulating the host immune 
response to invasion by pathogenic microorganisms (Holdsworth and Gan, 2015). 
 
1.4.2. The JAK/STAT Pathway 
Cytokine signalling is mediated by the Janus kinase (JAK) – STAT (JAK/STAT) 
pathway (Figure1.4) (Harrison, 2012). Upon cytokine binding, receptors associated with 
tyrosine kinases known as Janus kinases (JAKs) dimerize. Formation of receptor homodimers 
allows JAKs to cross-phosphorylate each other and receptor cytoplasmic domain tyrosine 
residues, which create docking sites for SH2-containing proteins such as STAT (signal 
transducer and activator of transcription) proteins. STAT dimers translocate to the nucleus, 
where they act as transcriptional activators by binding to enhancer sequences in target genes 




1.4.3. Regulation of JAK/STAT Signalling 
The JAK/STAT pathway is regulated by STATs, SOCS (suppressor of cytokine 
signalling) proteins, and PTPs (Protein tyrosine phosphatases) (Seif et al., 2017). SOCS protein 
dysregulation is thought to result in inappropriate STAT activation and account for the well-
documented involvement of STATs in cancer (Inagaki-Ohara et al., 2014). The roles of SOCS1 
and SOCS3 in cancer have also been particularly well studied. Both are powerful JAK 
inhibitors, capable of dysregulating essential cytokine-mediated processes such as 
proliferation, differentiation, maturation and apoptosis (Jiang et al., 2017, Inagaki-Ohara et al., 
2014).  
Figure 1.4. The Janus kinase / signal transducers and activators of transcription (JAK/STAT) 
pathway. Upon cytokine binding, JAKS form homodimers which create docking sites for STAT and its 
related proteins via cross-phosphorylation. STAT dimers act as transcriptional activators of genes in the 




The SOCS family of proteins consists of 8 proteins: SOCS1 to SOCS7 and CIS 
(cytokine-inducible SH2 protein) (Krebs and Hilton, 2001). In response to cytokine signalling, 
SOCS1, SOCS2, SOCS3 and CIS transcripts are upregulated, causing inhibition of JAK/STAT 
signalling pathways via negative feedback. The proteins inactivate JAKs, block STAT binding 
sites and ubiquitinate signalling proteins, making them targets for proteasomal degradation 
(Krebs and Hilton, 2001).  
 
1.4.4. STAT3 and Intestinal Homeostasis 
STAT proteins are latent transcription factors activated by cytokines and growth factors 
(Darnell et al., 1994, Gadina et al., 2001). STAT3, one of the seven members of this protein 
family is a transcription factor capable of regulating the growth, apoptosis, survival and 
migration of a variety of cell types (Akira, 2000). In the intestine STAT3 regulates IEC 
homeostasis, and its dysregulation here has been linked with both the innate and acquired 
immune responses involved in IBD and CRC development (Lovato et al., 2003, Sugimoto, 
2008, Corvinus et al., 2005) 
The correlation between STAT3 dysregulation and IBD has been well studied in mice. 
Although the exact cause of IBD remains unclear, there is abundant evidence implicating an 
abnormal response of the intestinal immune system to the gut microflora (Strober et al., 2007). 
Furthermore, overexpression of Interleukin-6 and -22 (IL-6 and IL-22) has been linked with 
human IBD development (Reinecker et al., 1993, Brand et al., 2006). IECs are crucial in the 
innate immune defence of the intestine. In wild type mice, active phosphorylated STAT3 
(pSTAT3) became detectable in 80% of IECs within 5 days of colitis development. Moreover, 
the effects of experimentally induced colitis in mice varied between those with IEC-specific 
STAT3 knockouts (STAT3IEC-KO) and controls.  STAT3IEC-KO mice demonstrated reduced 
20 
 
expression of STAT3 transcriptional targets including SOCS3 (see 1.4.5). Furthermore, 
STAT3IEC-KO mice were subject to increased tissue damage, crypt ablation, increased apoptosis, 
delayed intestinal healing and reduced proliferation (Pickert et al., 2009). The acquired immune 
response requires STAT3 activation to prevent T cell apoptosis and induce IL-6-dependent T 
cell proliferation. T cells subject to STAT3 deletions do not proliferate in response to IL-6 
signals as apoptosis is not prevented (Takeda et al., 1998).  
Following the recognition of constitutive STAT3 activation in various human 
malignancies, Corvinus and colleagues observed similar dysregulation in numerous CRC 
cases. Importantly, similar constitutive STAT3 activation to that observed in other human 
cancers was identified in neoplastic intestinal epithelial tissue, but not in normal adjacent tissue. 
This suggested a direct involvement of STAT3 in tumour development. CRC-derived cell lines 
were cultured, but critically lost their sustained STAT3 activity as a result (Corvinus et al., 
2005). The indisputable inference here – that aberrant STAT3 activation relies on external 
stimuli – was poorly understood until recently, when Heichler and colleagues discovered that 
STAT3 is activated in cancer associated fibroblasts (CAFs), causing proliferation of cells 
responsible for shaping the CRC tumour microenvironment (Heichler et al., 2020). 
 
1.4.5. SOCS3 and Intestinal Homeostasis 
SOCS3 is a vital regulator of disease. Its expression is upregulated in myeloid, 
lymphoid and some non-haematopoietic cells in response to infection and inflammation, such 
that it may bind JAK kinases or cytokine receptors, inhibiting STAT3 activation (Carow and 
Rottenberg, 2014). 
Like all SOCS proteins, SOCS3 contains an N terminal domain, a central SH2 domain 
and a SOCS box (Hilton et al 1998). Furthermore, SOCS3 possesses an extended SH2 
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subdomain (ESS), a kinase inhibitory region (KIR) and a proline, glutamine, serine, threonine 









Given the ability of SOCS3 to regulate JAK/STAT signalling, this essential protein also 
contributes to the maintenance of intestinal homeostasis by restricting IEC proliferation whilst 
permitting renewal and repair of dead and damaged IECs. Downregulation of SOCS3 in the 
intestinal epithelium is conducive to increased IEC turnover and hyperproliferation, which 
facilitates tumourigenesis (Rigby et al., 2007). This also alludes to a tumour suppressive role 
of SOCS3 (Shaw et al., 2017). However, complete knockout results in embryonic lethality due 
to overexpression of STAT3 and MAP kinase (Carow and Rottenberg, 2014). On the contrary, 
SOCS3 overexpression can be equally problematic, inhibiting JAK/STAT signalling and 
contributing to IBD development (Li et al., 2013).  
The role of SOCS3 in the intestine has been studied using Trichuris muris in murine 
intestine as a model for the human gastrointestinal parasite Trichuris trichiura (Whipworm) 
(Shaw et al., 2017). Whilst high dose infection causes expulsion of the parasite, low doses 
Figure 1.5. The structure of SOCS3. By binding phosphotyrosine-containing ligands such as JAK2, the 
SH2 domain of SOCS3 accounts for its inhibitory effects on the JAK/STAT pathway (Lu et al 2020). 
Meanwhile the KIR binds JAKs, blocking the active site and preventing substrate binding (Linossi et al 
2013). The PEST motif is an insertion motif within the SH2 domain and is responsible for the regulation of 
SOCS3 turnover. Figure from (Fletcher et al., 2009). Figure from (Babon et al., 2006). 
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cause chronic infection and increased SOCS3 mRNA expression at the site of infection, 
compared to high dose subjects. Further investigation revealed that upregulation of SOCS3 
inhibits IEC proliferation, rendering the host unable to expel the parasite. Meanwhile, 
downregulation resulted in increased IEC turnover and parasitic expulsion in infected mice but 
did not confer resistance to T. muris infection relative to uninfected controls (Shaw et al., 2017). 
This was thought to be due to an increased expression of the immunosuppressor enzyme 
indoleamine 2,3-dioxygenase (IDO) which is degraded by SOCS3 (Orabona et al., 2004). 
IDO is upregulated in the gut in response to inflammation, although some studies have 
observed increases following chronic T. muris infection (Datta et al., 2005). Such results may 
be attributed to the increased number of IDO-expressing goblet cells associated with 
hyperplasia. SOCS3 inhibits IDO via proteasomal degradation and has been shown to induce 
T. muris resistance in models by facilitating migration of cells up crypts. This so-called 
“epithelial escalator” expels worms without reducing crypt depth. Furthermore, knockout 
mouse goblet cells express more IDO than those of controls (Bell and Else, 2011). Without the 
action of SOCS3, uninhibited IDO allows worm survival by impeding the epithelial escalator.  
 
1.4.6. IRF3 in Viral Infection  
The presence and threat of pathogens in the body is detected by highly specialised 
pattern recognition receptors (PRRs) which bind evolutionarily conserved pathogen-specific 
motifs known as pathogen associated molecular patterns (PAMPs) expressed by invading 
pathogens as well as damage associated molecular patterns (DAMPs) expressed by damaged 
self-cells (Mogensen, 2009, Tang et al., 2012). Multiple PRRs have been identified to date, 
with most belonging to one of 4 families: toll-like receptors (TLRs), retinoic acid-inducible 
gene-I-like receptors (RIG-I-like receptors or RLRs), nucleotide-binding oligomerization 
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domain-like receptors (NOD-like receptors or NLRs) and C-type lectin receptors (CLRs) 
(Takeuchi and Akira, 2010). In addition, the receptor for advanced glycation end products 
(RAGE) has also been identified as a PRR (Teissier and Boulanger, 2019). Association 
between PRRs and either PAMPs or DAMPs initiates intracellular signalling cascades which 
culminate in an immune response (Tang et al., 2012).   
The discovery of the Interferon Regulatory Factor (IRF) protein family began in 1988, 
with the identification of the first of nine members. The so-called IRF-1 protein is a nuclear 
factor which regulates the transcription of IFN-β (Miyamoto et al., 1988). It was not until 1995 
that Au and colleagues identified IRF3, which is now understood to be a key transcription 
factor in the response to viral infection (Au et al., 1995). IRF3 remains inactive in the cytoplasm 
until, upon stimulation, C terminus phosphorylation permits its dimerization and translocation 
into the nucleus (Yoneyama et al., 1998, Lin et al., 1998). Nuclear IRF3 binds DNA and 
induces the transcription of type 1 interferon (type I IFN) genes, then is degraded by the 
proteasome (Lin et al., 1998).   
Viral infection may be detected due to the presence of viral DNA or double-stranded 
RNA (dsRNA) within the cell. The response relies on the phosphorylation of IRF3, mediated 
by one of three adapter proteins: Stimulator of interferon genes (STING), mitochondrial 
antiviral signalling (MAVS) or Toll/IL-1R resistance domain–containing adapter-inducing 
IFN-β (TRIF). Exactly which adapter protein is recruited is determined by the PAMP detected 
and signalling pathway induced. The STING signalling pathway, activated by the presence of 
viral RNA in the cytosol, is discussed later in detail (see 1.4.7) and will not be discussed here. 
The presence of dsRNA in the cytosol is detected by RLRs (Yoneyama et al., 2004). 
RLRs contain C-terminal repressor domains (RDs) which prevent the N terminal caspase 
activation and recruitment domains (CARDs) from interacting with downstream signalling 
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pathway components in unstimulated cells (Saito et al., 2007). Ligand binding liberates 
CARDs, which are thereby free to facilitate the recruitment of MAVS (Cui et al., 2008, Kawai 
et al., 2005).  Phosphorylation of MAVS by TANK-binding kinase 1 (TBK1) or IκB kinase 
(IKK) creates a binding site for IRF3 which, once bound, is also phosphorylated by TBK1 (Liu 
et al., 2015). Phosphorylated IRF3 dimerizes and translocates to the nucleus, where it associates 
with the co-activators CREB-binding protein and p300 (CBP/p300) and drives the expression 
of type I IFN genes (Seth et al., 2005, Yoneyama et al., 1998, Lin et al., 1998). Phosphorylation 
of MAVS may mediate IRF7 and nuclear factor kappa B (NF-κB) activation as well as IRF3 
(Tang and Wang, 2009, Seth et al., 2005). 
Whilst TLRs are a major subset of PRRs, IRF3 is activated in response to PAMP 
recognition by TLR3 and TLR4 only (Doyle et al., 2002). Intracellular TLR3 binds viral double 
stranded RNA, meanwhile cell surface TLR4 (initially identified as the signalling receptor for 
lipopolysaccharides of gram-negative bacteria) also binds some viral proteins (Alexopoulou et 
al., 2001, Kurt-Jones et al., 2000, Mogensen and Paludan, 2005, Hoshino et al., 1999). TLRs 
bind their respective ligands and recruit Toll/IL-1R resistance (TIR) domain–containing 
adapter proteins which in turn initiate the signalling pathways necessary to orchestrate a 
response. TLR3 and TLR4 activate IRF3 via the TRIF pathway. TRIF interacts directly with 
TLR3 following receptor phosphorylation by the epithelial growth factor receptor (ErbB1) or 
Bruton’s tyrosine kinase (Btk) (Yamashita et al., 2012, Lee et al., 2012). Alternatively, indirect 
interaction between TRIF and TLR4 is facilitated via TIR-containing adapter molecule 
(TICAM)-2, also known as TRIF-related adapter molecule (TRAM) (Oshiumi et al., 2003). 
TRIF then activates TBK1 and IKKε, which phosphorylate IRF3 (Jiang et al., 2004). 
Through an independent signalling pathway, IRF3 also acts as an apoptotic factor in 
the virus-infected cell. Through its BH3 domain, IRF3 interacts with the Bcl-2 family member 
Bax, with which it then translocates to the mitochondria (Chattopadhyay et al., 2010). In the 
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mitochondria, Bax oligomers are inserted into the mitochondrial membrane, which make it 
permeable to the cytochrome complex and activates the mitochondrial apoptotic pathway 
(Antonsson et al., 2001, Lovell et al., 2008). 
 
1.4.7. STING in Defence Against Microbes  
STING is an endoplasmic reticulum (ER)-bound adaptor protein central to the response 
to viral infection (Ishikawa and Barber, 2008). Detection and binding of microbial or self-DNA 
by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) in the 
otherwise DNA-free cytoplasm is sufficient to activate the innate immune response. STING 
elicits anti-microbial responses by inducing Type I and III IFNs or activating autophagy (Figure 
1.6) (Sun et al., 2013, Deb et al., 2020, Gui et al., 2019).  
The cGAS-STING signalling cascade induces type I and III IFNs to regulate 
inflammation by activating the transcription factors IRF3 and NF-κB. The STING-NF-κB 
pathway is incompletely elucidated but is known to employ TBK1 and induce Type I IFN 
expression (Cerboni et al., 2017, Abe and Barber, 2014). The STING-IRF3 pathway, however, 
is well understood. Activated cGAS catalyses a reaction between adenosine triphosphate (ATP) 
and guanosine triphosphate (GTP) to form cyclic guanosine monophosphate-adenosine 
monophosphate (cGAMP) (Zhang et al., 2013, Ablasser et al., 2013). cGAMP binds STING to 
induce a conformational change which activates and displaces it from the ER (Wu et al., 2013). 
Activated STING oligomerizes and recruits TBK1, which creates binding sites for IRF3 (Zhang 
et al., 2019). Upon recruitment to these sites, IRF3 is phosphorylated by TBK1 before it 
dimerizes, translocates to the nucleus and mediates expression of target genes.  
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The cGAS-STING cascade can also activate autophagy to clear the cytosol of 
stimulatory DNA. The interaction between cGAMP and STING drives its translocation to the 
endoplasmic reticulum-Golgi intermediate compartment (ERGIC), where it facilitates LC3 
lipidation to the autophagosome component LC3-II. cGAMP-induced autophagosome 












With regards to IFN induction, the cGAS-STING signal transduction cascade invokes 
the secretion of type I IFNs in most cells (Zhao et al., 2016). Type III IFNs are secreted by a 
smaller selection of cell types including plasmacytoid dendritic cells (pDCs) according to a 
recent study (Deb et al., 2020). Type I IFNs readily activate the JAK/STAT signalling pathway 
Figure 1.6. Activation of the cGAS-STING pathway by cytosolic dsDNA. STING regulates innate 
immunity via activation of autophagy or downstream factors IRF3 and NF-κB. Figure adapted from 




by binding the IFNα receptor (IFNAR), which is composed of IFNAR1 and IFNAR2 subunits 
(Darnell et al., 1994, Uzé et al., 1990). Meanwhile, type III IFNs activate the JAK/STAT 
pathway through binding the interleukin-28 receptor (IL-28R), which is composed of IFN-λR1 
and IL-10R2 (Kotenko et al., 2003). Type I and III IFN binding to their respective receptor 
induces dimerization and phosphorylation of tyrosine kinase 2 (TYK2) and JAK1. STAT1 and 
STAT2 are phosphorylated by the JAKs and form a heterodimer. The STAT1-STAT2 dimer 
translocates to the nucleus and associates with IFN regulatory factor 9 (IRF9) to form the IFN-
stimulated gene factor 3 (ISGF3) complex (Dale et al., 1989, Schindler et al., 1992). ISGF3 
binds IFN-stimulated response elements (ISREs) in the promoter region of some IFN-
stimulated genes (ISGs) and drives their transcription (Reich et al., 1987). Upregulation of 
ISGs creates a potent anti-viral environment within the cell (Figure 1.7) (Ivashkiv and Donlin, 
2014, Schneider et al., 2014). 
The STING-cGAS pathway has received positive publicity in the field regarding its 
proposed role in cancer protection. Its repression is reported in ovarian cancers, meanwhile its 
activation induces apoptosis in malignant cells, indicating a tumour suppressive role (de 
Queiroz et al., 2019, Tang et al., 2016). Specifically, STING signalling offers protection against 
the oncogenic effects of abnormal DNA (Kwon and Bakhoum, 2020). Genomic instability is a 
hallmark of cancer and may manifest as fluctuations in chromosome number and structure 
(Hanahan and Weinberg, 2011, Geigl et al., 2008). This flux - known as chromosomal 
instability - eventually causes surplus DNA to erupt from micronuclei into the cytosol, where 
it can activate cGAS and initiate the STING signalling cascade (Bakhoum et al., 2018). STING 
also stimulates immunogenic autophagy by interacting with LC3, before being degraded itself 
(Liu et al., 2019).  
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The virome must infect both prokaryotic and eukaryotic cells within the gut in order to 
persist. In host cells, such interactions cause activation of the cGAS-STING pathway, which 
raises the possibility that the microbiota is capable of influencing the body’s response to cancer 
















Figure 1.7. Type I and III IFN signalling culminating in upregulation of antiviral genes via the 
JAK/STAT pathway. JAK1 and TYK2 are activated by binding of type I IFNs to the IFNAR, or type III 
IFNs to the IL-28R. Activation induces dimerization of STAT1 and STAT2, which complex with IRF9 to 
form the ISGF3. In the nucleus the ISGF3 binds ISREs and regulates the transcription of ISGs to mediate 




Autophagy is the cellular mechanism responsible for the lysosomal degradation of 
cytoplasmic components including proteins and organelles (Mizushima et al., 2008). 
Conserved from yeast to humans, autophagy can be observed throughout eukaryotic cells, with 
3 types identified in mammalian cells (Levine and Deretic, 2007, Parzych and Klionsky, 2014). 
These are known as macroautophagy, microautophagy and chaperone-mediated autophagy 
(CMA).  
First described in 1966 by Christian De Duve and Robert Wattiaux, microautophagy 
involves deformation of the lysosomal membrane in order to trap a region of the cytosol which 
includes, but is not limited to, proteins and organelles (Cuervo and Dice, 1998). Cytoplasmic 
components therefore become trapped within invaginations, which eventually bud off into the 
lysosome, engulfing the cargo (Figure 1.8a.) (De Duve and Wattiaux, 1966). 
Macroautophagy also involves sequestration of an entire portion of the cytosol and its 
constituents, however in this process cargo becomes trapped within a double-membraned 
autophagosome which is synthesised de novo (Cuervo and Dice, 1998). The so-called 
autophagic body – comprised of the inner membrane and the intra-autophagosomal 
components – is released into the lysosomal lumen upon fusion between the lysosome and 
autophagosome and degraded by lysosomal hydrolases (Figure 1.8b) (Yorimitsu and Klionsky, 
2005, Tanida et al., 2008). 
Chaperone-mediated autophagy involves a highly specific selection of cytosolic 
proteins, and their subsequent sequestration via translocation into the lysosome. CMA is 
activated when the 73kDa heat shock cognate protein Hsc73 or Hsc70 binds KFERQ-like 
sequences of substrate proteins in the cytosol (Terlecky and Dice, 1993) (Cuervo and Wong, 
2014). Chaperone-bound proteins interact with monomeric lysosome-associated membrane 
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protein type 2A (LAMP-2A protein) at the surface membrane of the lysosome (Cuervo and 
Dice, 1996). This interaction initiates formation of a translocation complex consisting of 
LAMP-2A homotrimers which interact with Hsc70 chaperones (Cuervo and Wong, 2014); 
(Rout et al., 2014). LAMP-2A homotrimers are stabilised at the lysosomal surface and 
disassemble, meanwhile lysosomal Hsc70 drives KFERQ-like motifs of substrate proteins into 
the lysosomal lumen for degradation (Bandyopadhyay et al., 2008).  
As the most common and well-studied form, the term ‘autophagy’ shall now refer to 
macroautophagy alone. Paradoxically, this process which is dedicated to self-destruction 
supports cell survival. Whilst autophagy is primarily activated in response to metabolic stresses 
in yeast and other unicellular organisms (Tsukada and Ohsumi, 1993), it is activated in many 
mammalian cells during periods of fasting. A 2003 study identified autophagy induction in 
skeletal muscle, liver, heart, kidney and other GFP-LC3 transgenic mouse tissues following 
24-hour food deprivation (Mizushima et al., 2004). Furthermore, mammalian neonates induce 
autophagy immediately at birth for in order to compensate for the termination of nutrient supply 
from the placenta until the requirement can be met by milk (Kuma et al., 2004). This allows 
cells to maintain their metabolic functions. Degraded cargo is returned to the cytosol to create 
a pool of metabolites which can be utilised throughout periods of nutrient deprivation (Lum et 
al., 2005b). 
Microtubule-associated protein 1A/1B-light chain 3 (LC3) is a soluble protein which is 
widely used to study autophagy in mammalian cells. Upon activation of autophagy, LC3 is 
cleaved to form cytosolic LC3-I, which is conjugated to phosphatidylethanolamine to form the 
autophagosome membrane component LC3-II (Tanida et al., 2008, Koukourakis et al., 2015). 
Fusion of autophagosomes with lysosomes releases intra-autophagosomal cargo, including 
membrane-bound LC3-II, into the lysosomal lumen. This LC3 flux has branded it a reliable 
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marker of autophagy, making it a popular target for immunoblotting using Anti-LC3 antibodies 


















Figure 1.8. Degradation of cytosolic components by micro- and macroautophagy.  
a) During microautophagy cytosolic components become sequestered within invaginations in the 
lysosomal membrane and are subsequently degraded by lysosomal hydrolases. 
b) During macroautophagy cytosolic components become trapped within a double-membraned 
autophagosome, forming an autophagic body. Fusion of the autophagosome with the lysosome releases 
the autophagic body for degradation by lysosomal hydrolases. 




There are three distinct human isoforms of the LC3 protein, known as LC3A, LC3B 
and LC3C (He et al., 2003). One study found LC3A and LC3C to co-localize in the nucleus of 
cancer cell lines. Meanwhile LC3B expression is poor throughout the nucleus, but common in 
the LC3A-negative nucleolus. Whilst cytoplasmic LC3A expression is restricted to the 
perinuclear space, LC3B and LC3C are expressed throughout, although it is important to note 
that co-localization has not been observed here (Koukourakis et al., 2015). Of the three human 
LC3 isoforms, LC3B is the best understood and is therefore widely recognised as the most 
dependable marker of autophagic flux in cells.  
The haploinsufficient tumour suppressor protein beclin-1 is central to the regulation of 
autophagy and is often deleted in cancer (Yue et al., 2003, Aita et al., 1999). Under normal 
conditions, beclin-1 is inhibited by interactions with members of the anti-apoptotic B-cell 
lymphoma-2 (Bcl-2) protein family. When cells are subject to short periods of stress such as 
nutrient deprivation, beclin-1 dissociates from its inhibitory complex and induces autophagy 
(Pattingre et al., 2005). In humans, beclin-1 binds phosphatidylinositol 3-kinase (hVps34), 
UVRAG, hVps15, Atg14L and Rubicon to form three distinct complexes, at their core a beclin-
1-hVps34-hVps15 complex (Kihara et al., 2001, Liang et al., 2006, Matsunaga et al., 2009). 
UVRAG (UV radiation resistance associated gene) and Atg14L (Autophagy-related 14-like) 
bind the same region of this complex under different conditions, to regulate beclin-1 mediated 
autophagy. Meanwhile Rubicon (Run domain beclin-1 interacting and cysteine-rich domain-
containing protein) binds just a few pre-existing UVRAG complexes in order to negatively 
regulate autophagy (Matsunaga et al., 2009).  
Autophagy dysfunction has been linked with a plethora of diseases (Mizushima et al., 
2008). Among these are pathogenic infection, neurodegeneration, heart disease, ageing and 
cancer. The relationship between autophagy and cancer is complex. As mentioned, autophagy 
promotes survival by providing cells with the means to degrade organelles and proteins, recycle 
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nutrients and sustain metabolic reactions under stress. In healthy somatic cells, maintenance of 
cell viability under metabolic stress is of course beneficial to the host. However, in malignant 
cells this promotes tumourigenesis and can be detrimental. The early tumour microenvironment 
is poorly oxygenated due to compromised blood supply. Induction of angiogenesis is one of 
the hallmarks of cancer and has been found to be stimulated by autophagy (Liang et al., 2018, 
Hanahan and Weinberg, 2011). Furthermore, developing tumours are deprived of nutrients but 
require a surplus to grow. Autophagy-mediated recycling of cellular components can sustain 
starved cells for prolonged periods and provide tumours with the means to progress for many 
weeks (Lum et al., 2005a).  
In light of the profound effects of autophagy activation on tumour survival, it is almost 
incomprehensible that it is beneficial to the host in the early stages of cancer. When autophagy 
is blocked at this stage, immunosuppressive T regulatory (Treg) cells infiltrate tumours and 
suppress immune responses to it (Rao et al., 2014). In contrast, upregulation of beclin-1 
expression in colon cancer cells inhibits tumourigenesis (Koneri et al., 2007). Activation of 
autophagy is therefore initially necessary to prevent immune tolerance to, and growth of, 










1.5. Project Aims  
Inflammatory signalling and autophagy are key pathways involved in intestinal 
epithelial homeostasis and maintenance. Dysregulation of these pathways can be detrimental 
to the host, leading to cancer and IBD. We hypothesise that SOCS3 in the intestinal epithelium 
is a regulator of microbial-mediated signalling pathways. To investigate this, we aim to create 
two models of dysbiosis using human intestine starved of enteral nutrition and cells transfected 
with exogenous DNA. We will use these models to investigate the impact of dysbiosis upon 
inflammatory signalling pathways and autophagy. Furthermore, we aim to use transgenic cell 
lines to investigate the role of SOCS3 in these pathways.  
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2. Materials and Methods 
2.1. Cell Lines 
2.1.1. Maintenance  
Cells were transfected with empty vector or SOCS3 expression plasmids to create 
control (SOCS3EV) and overexpressing (SOCS3high) cell lines, respectively. SOCS3 and non-
silencing shRNA GIPZ lentiviral constructs (Thermo Scientific) were used to produce a SOCS3 
knockdown (SOCS3low) cell line, as described in Shaw et al, 2017. Human intestinal epithelial 
cell (HIEC) medium was prepared using Opti-MEM, 5% foetal bovine serum, 5mM HEPES 
and 10μg/ml EGF. Cells were cultured in HIEC medium with either 0.5mg/ml G418 
(SOCS3high) or 0.4μg/μl puromycin (SOCS3EV and SOCS3low) added. Cells were maintained 
in T75 (75ml) culture flasks and passaged every second day, or at 70% confluence. Cells were 
passaged under sterile conditions using a laminar flow cabinet. Media from all flasks was 
discarded and cells were washed with 5ml of Dulbecco’s Phosphate-Buffered Saline (DPBS) 
from ThermoFisher Scientific before being incubated with 1ml Trypsin-EDTA for 10 minutes. 
Tryspinised cells were diluted to approximately 2 x 105 cells/ml and incubated at 37°c for 48 
hours, or until 70% confluence was reached.  
 
2.1.2. Plating Cells  
Media was discarded and HIECs were washed with DPBS and trypsinised. 5ml of HIEC 
medium was added to each flask and homogeneous flasks were mixed. 10μl of each suspension 
was removed and mixed with 10μl 0.4% trypan blue (Sigma T8154) in an Eppendorf tube. 10μl 
of stained suspension was loaded to a haemocytometer and observed at 100 x magnification 
using the brightfield microscope. Live, unstained cells within the 1mm2 area in each corner of 
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the grid were counted and the mean of these values was multiplied by 104 to obtain the number 
of live cells per ml (cm3) of solution. Finally, the concentration of live cells per ml was 
multiplied by 2 as the cells were diluted 1:1 with Trypan Blue. 
Suspensions of each cell line at a concentration of 200,000 cells/ml in HIEC medium 
were used to prepare a 12-well plate for each cell line. Each well received 200,000 cells in 1ml 
of suspension and was incubated at 37°c overnight.  
 
2.1.3. Transfecting Cells 
Cells were either untreated controls, were transfected with Herring Sperm DNA using 
the K4 transfection system by Biontex (DNA-treated), were transfected with K4 transfection 
reagent only (K4 control) or were used for mRNA analysis (see 2.3) and this was done in 
triplicate. Herring sperm DNA (8μg/μl) and the K4 transfection system were brought to room 
temperature and agitated gently to ensure even mixing. Media was removed from all wells and 
200μl complete growth medium was added to controls. Complete growth medium and K4 
multiplier (200μl and 2μl, respectively) was added to all treated wells. Plates were incubated 
at 37°c for 30 minutes. Solutions of Herring sperm DNA and K4 transfection reagent were 
prepared according to the manufacturer protocol. In order for each well to receive 1μg of DNA, 
1.2μl of 8μg/μl DNA stock was mixed with 135μl of serum-free medium and 15μl of this 
solution was pipetted into each K4-treated well. 18μl of K4 transfection reagent was mixed 
with 370μl serum-free medium in a separate tube and 15μl of this solution was pipetted into 
each DNA-treated and K4-treated well. This was repeated for all 3 plates, which were then 





2.1.4. Cell Lysis 
Cell lysis solution was prepared by mixing lysis buffer 100:1 with both protease 
inhibitor P8340 and phosphatase inhibitor P5726 by Sigma. Media was removed from control 
and treated wells, and 200μl of cell lysis solution was added. The adherent HIEC cells were 
dislodged from the well surface into the solution, transferred to an Eppendorf tube and stored 


















2.2. Western Blot 
Laemmli sample buffer (4x; Bio-Rad #1610747) was mixed with β-mercaptoethanol in 
a 9:1 ratio, and added to samples in a 3:1 (sample:buffer) ratio. Samples were boiled at 95°c 
for 5 minutes to denature the proteins and then loaded onto a prepared Mini-PROTEAN TGX 
gel (Bio-Rad #4569036). Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS 
PAGE, 200V) was used to separate the proteins according to molecular weight. Proteins were 
transferred onto nitrocellulose membranes using the Trans-Blot Turbo Transfer system (Bio-
Rad #17001918). Membranes were incubated in blocking buffer (5% BSA in TBST) for 1 hour 
at room temperature to prevent non-specific binding and then overnight at 4°c in primary 
antibody solution (Table 2.1). Membranes were washed 3 times in TBST (1% Tween) for 10 
minutes and then incubated for 1 hour at room temperature in secondary antibody solution 
(Table 2.1). Primary and secondary antibodies were diluted in blocking buffer and TBST 
respectively, in accordance with supplier instructions. Membranes were washed twice for 10 
minutes in TBST, then once for 10 minutes in TBS. ECL substrate (Bio-Rad #1705060) was 
applied for 5 minutes. Membranes were imaged using the ChemiDoc System by Bio-Rad and 
analysed using Image Lab software. Densitometry analysis was used to quantify and 
standardise the expression of all proteins relative to constitutively expressed β-actin.  
Antibody Supplier Product number 
pSTAT3 Santa Cruz Biotechnology Sc-0859 
STAT3 Cell Signalling #9139 
STING Cell Signalling #13647 
SOCS3 Cell Signalling #2932 
β-actin Cell Signalling #3700 
LC3B Cell Signalling #3868 
Beclin-1 Cell Signalling #3495 
Anti-mouse Cell Signalling #7076 
Anti-rabbit Cell Signalling #7074 
 




2.3. qPCR Analysis 
2.3.1. mRNA Extraction 
For cell analysis, media was removed from wells and 200μl TRI reagent (Sigma T9424) 
was added. Adherent cells were dislodged into TRI, transferred to Eppendorf tubes, and stored 
on ice overnight. For tissue analysis, homogenised tissue samples stored in TRI reagent (Sigma 
T9424) at a concentration of approximately 50mg/ml were thawed at room temperature. 
Chloroform (Sigma 319988) was added (200μl per 1ml of TRI) and samples were 
shaken vigorously, incubated at room temperature for 10 minutes and centrifuged at 12,000g 
for 15 minutes at 4°c. Upper aqueous phases were transferred to sterile Eppendorf tubes and 
the lower phases were discarded. 2-propanol (Sigma I9516) was then added (500μl per 1ml of 
TRI reagent) and samples were incubated at room temperature for 10 minutes, then centrifuged 
at 12,000g for 10 minutes at 4°c. Supernatant was discarded, then RNA pellets were washed 
with a minimum of 1ml 75% ethanol per 1ml of TRI reagent. Samples were vortexed and then 
centrifuged for 5 minutes at 7,500g. Excess ethanol was removed, and samples were air dried 
at room temperature for 10 minutes. Pellets were dissolved in nuclease free water (30μl for cell 
analysis, 100μl for tissue analysis) by pipetting. The concentration and purity of mRNA was 
determined using the Thermo Scientific NanoDrop 2000 spectrophotometer.  
 
2.3.2. Reverse Transcription  
cDNA was generated from 1μg of mRNA. mRNA (1μg) in solution was transferred to 
a sterile Eppendorf tube and volume was made up to 12μl using nuclease-free water. 0.5μl of 
oligo(dT) primer was added and the tubes were incubated at 65°c for 5 minutes, centrifuged 
briefly and stored on ice. Each tube received 4μl 5x reaction buffer (Thermo), 1μl 10mM dNTP 
(Fermentas) and 1μl of Revertaid reverse transcriptase (Thermo #EP0441). Reactions were 
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incubated at 42°c for 60 minutes, then at 70°c for 10 minutes. Resulting cDNA was stored on 
ice until further use.   
 
2.3.3. qPCR  
Relative SOCS3 expression was measured using qPCR and normalized through 
comparison with expression of the housekeeping gene ribosomal protein lateral stalk subunit 
P0 (RPLP0). Cycle threshold (Ct) values for both genes in each cell line were used to calculate 
the ΔCt, which normalises SOCS3 expression against the control. SOCS3 expression was then 
calculated as fold change relative to empty vector controls. hSOCS3 and RPLP0 forward and 
reverse primers (100μM) were diluted 10-fold with nuclease-free water. Master Mix was 
prepared using either hSOCS3 or RPLP0 primers, and sufficient volumes were prepared to run 
all samples in duplicate, according to manufacturer instructions. Real-Time PCR was 
performed using SYBR Green JumpStart Taq ReadyMix, 10μM forward primer, 10mM reverse 
primer and nuclease-free water by Sigma. Master mix (19μl) was aliquoted into all plate wells. 
cDNA and nuclease-free water (1μl each) were added to test wells and no template control 
wells, respectively. Cycling conditions were 94°C for 2 min, 40 × 94°C for 15 s, and 60°C for 
1 min. Primer sequences used to amplify hSOCS3 were as follows. Forward: 5’-
GGCCACTCTTCAGCATCTC and Reverse: 5’-ATCGTACTGGTCCAGGAACTC. Primer 







2.4. Intestinal Tissue Homogenisation  
From each of 13 patients undergoing loop ileostomy surgery reversal, one functioning 
and one defunctioned ileal resection specimen was obtained and stored at -80°c. Cell lysis 
solution was prepared using lysis buffer, protease inhibitor and phosphatase inhibitor in a 
1000:1:1 ratio. Samples were weighed and the volume of lysis buffer required to achieve total 
protein concentrations of approximately 10mg/ml of homogenized tissue were calculated. 
Tissue samples were bisected accordingly and homogenized in lysis solution to extract the 
protein content. Samples were homogenized using the LabGEN 125 tissue homogenizer by 
Cole-Palmer and stored at -80°c.  
 
2.5. Bradford Assay  
Protein concentration was determined using the Bradford assay. Bradford reagent was 
brought to room temperature. Protein standards ranging from 5mg/ml to 0.156mg/ml were 
prepared by conducting a 2-fold serial dilution of BSA in 1 x PBS. Homogenised tissue samples 
in lysis buffer were thawed on ice. The range of protein concentrations detectable by the 
Bradford assay is 0.1–1.4 mg/ml. Samples were homogenised at approximately 10mg/ml and 
therefore were diluted 10-fold to fall within this range. 5μl of BSA standards were pipetted into 
6 of the 96 wells, and 6μl of 1 X PBS only was pipetted into the seventh. 5μl of protein samples 
(concentrations unknown) were pipetted into subsequent wells in duplicate. 250μl of Bradford 
reagent was added to all control and test wells and mixed gently. Absorbance at 595nm was 
measured using the Tecan spectrophotometer. Net absorbance by BSA protein standards at 
595nm was calculated and used to create a standard curve from which the concentrations of 




2.6. Measurement of Villous Height  
Tissue biopsies from functioning and defunctioned intestine were examined using a 
Motic BA210E microscope at 200x magnification. Sections were fixed for 24 hours in 4% 
paraformaldehyde solution and haematoxylin and eosin (H&E) stained, as described in 
Beamish et al (Beamish et al., 2017). Scale was calculated using the line drawing function to 
mark the known distance between two hash marks on a graticule. Per patient, all villi which 
had not been structurally altered or impaired during preparation were identified and measured 
using the line drawing function (Figure 2.1). The biopsies examined were those prepared in 














Figure 2.1. Measurement of villous height. Scale was calculated using magnification and actual distance 
between 2 hash markings on a graticule. The line drawing function was then used to mark the distance 
between the base and apex of intact crypts seen in tissue sections fixed with 4% paraformaldehyde and 
stained with H&E stain.  
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3. The Impact of Microbiome Manipulation on Signalling 
in the Human Intestine 
3.1. Results 
Villi were measured in both the functioning and defunctioned intestine of each patient, 
and all measurements were grouped to form one set of data for functional tissue, and one for 
defunctioned. The biopsies examined were those prepared in Beamish et al (2017), which had 
not yet been analysed, therefore two individuals were used. Histological examination of the 
tissue revealed that loss of function caused atrophy, characterised by significant reductions in 












Figure 3.1. Villous height in functioning and defunctioned intestine of two patients. Tissue sections 
fixed in 4% paraformaldehyde and stained with H&E were examined at 200x magnification. In-tact villi 
were identified and measured from base to apex. All measurements taken from functional sections were 
grouped, and all from distal sections were grouped. Between the two patients, a total of 39 villi from the 
functional tissue sections, and 19 from the distal sections were measured (N=39 and 19, respectively). A 





The expression of inflammation signalling proteins STAT3, STING and SOCS3 was 
compared between tissue biopsies taken from functioning (F) and defunctioned (D) human 
intestine (Figure 3.2). Expression in defunctioned tissue was calculated as a percentage change 
from the expression in normal tissue. Outliers greater than two standard deviations from the 
mean were excluded. Patients 2 and 12 were consistently identified as outliers and excluded 
from the dataset. We find that bowel defunction did not significantly impact the expression of 
these inflammatory signalling proteins (Figure 3.3). This suggests that the observed reduction 
in villous height was not a consequence of the inflammatory signalling pathways studied, and 
substantiates the conclusion that chronic inflammation was not present at the time of reversal 




Figure 3.2. Western blot analysis of pSTAT3, STAT3, STING and SOCS3 in functioning (F) and 
defunctioned (D) intestinal tissue of 13 patients. Tissue biopsies were homogenised in cell lysis 
solution and the Bradford assay was used to roughly determine total homogenate protein concentration. 
The volume of homogenate containing 20μg of protein was calculated for each sample and made up to 
12μl with Milli-Q water, then 16μl with 4x Laemmli buffer. Proteins were separated by size using SDS-

















The role of autophagy in the reported villous atrophy was then examined using western 
blot to compare the expression of the marker of autophagy beclin-1 in the functioning and 
defunctioned tissue (Figure 3.4). Again, patients 2 and 12 were excluded from the dataset and 
the remaining samples were analysed. Expression in defunctioned tissue was calculated as a 
percentage change from the expression in normal tissue (Figure 3.5). There was a significant 
increase in beclin-1 expression upon loss of ileal function (p<0.05) which implicates autophagy 
in the atrophy of defunctioned tissue. 
Figure 3.3. Percentage change in activated STAT3, STING and SOCS3 in defunctioned bowel, 
relative to functioning tissue. Densitometry analysis was used to calculate normalised expression of 
activated STAT3, STING and SOCS3. The abundance of protein was determined relative to -actin in 
each sample. Normalised protein expression in the defunctioned bowel was then expressed as percent 
change from that in the functional tissue of each individual patient. STAT3 activation by phosphorylation 
at Tyr 705 was determined by calculating pSTAT3 as a proportion of total STAT3. Instances in which 
either the protein of interest or beta actin produced insufficient signal to obtain an accurate result were 

















Figure 3.5. Beclin-1 expression in functioning and defunctioned bowel. Densitometry analysis was 
used to determine the abundance of beclin-1 relative to -actin in each sample. Normalised beclin-1 
expression in the defunctioned bowel was expressed as percent change from that in the functional tissue 




 Figure 3.4. Western blot analysis of the autophagy marker beclin-1 in functioning and defunctioned 
intestinal tissue of 13 patients. Tissue biopsies were homogenised in cell lysis solution and the Bradford 
assay was used to roughly determine total homogenate protein concentration. The volume of homogenate 
containing 20μg of protein was calculated for each sample and made up to 12μl with Milli-Q water, then 
16μl with 4x Laemmli buffer. Proteins were separated by size using SDS-PAGE before beclin-1 and -actin 
were identified using western blot analysis.  
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4. The Impact of SOCS3 on Microbiome Signalling in 
Human Intestinal Epithelial Cells (HIEC) 
4.1. Results 
Microbiome modulation was modelled using DNA transfection in control SOCS3EV 
HIEC and the expression of inflammatory signalling proteins STAT3, STING and SOCS3 in 














Figure 4.1. Western blot analysis of STING, SOCS3, pSTAT3 and STAT3 in control empty vector 
(SOCS3EV) HIEC. Cells in each treatment group were transfected with K4 transfection reagent alone (K4 
controls), with DNA, or were unstimulated controls. Cells were lysed to extract the protein content, which 
was separated by SDS PAGE. Western blot analysis was used to determine relative expression of pSTAT3, 
STAT3, STING and SOCS3 signalling proteins, normalised against the housekeeping gene -actin. This 
was repeated in triplicate for each treatment group. 
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The expression of each protein within DNA-stimulated cells was determined relative to 
that in untreated controls, and the percentage change was calculated. Outliers greater than two 
standard deviations from the mean were excluded from the dataset. Although the results imply 
a tendency for increased SOCS3 and STAT3 activation, STING activation tends to decrease 
(Figure 4.2). The calculated p values were however non-significant and so modelling 
microbiome manipulation using DNA transfection did not affect the expression of 















Figure 4.2. Percentage change in SOCS3, STING and activated STAT3 in cells stimulated with 
DNA, relative to untreated controls. Densitometry analysis was used to calculate normalised expression 
of activated STAT3, STING and SOCS3. The abundance of each protein was determined relative to -
actin in each sample. Normalised protein expression in cells stimulated with DNA was then expressed as 
percent change from that in unstimulated controls. STAT3 activation by phosphorylation at Tyr 705 was 
determined by calculating pSTAT3 as a proportion of total STAT3. N = 7, 6 and 7, respectively. 
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We then sought to determine the effect of SOCS3 expression on the response of HIEC 
to DNA transfection. Firstly, qPCR verified that transgenic cells were expressing SOCS3 as 
intended. SOCS3 mRNA was normalized against the housekeeping gene RPLP0 (Figure 4.3a) 
and compared between the three cell lines.  Ct values confirmed that relative to empty vector 
controls, SOCS3 mRNA transcription was 30% lower and 55-fold greater in SOCS3low and 
SOCS3high cells, respectively (Figure 4.3b).  The expression of SOCS3 by SOCS3low, SOCS3EV 
and SOCS3high cells under normal conditions was normalised against β-actin. Within the first 
biological replicate, SOCS3 protein was present as expected in all three cell lines. However, 
within the second replicate, the protein levels in both transgenic cell lines appeared completely 
inversed; SOCS3low cells seemingly upregulated the protein relative to empty vector controls, 
and SOCS3high the contrary. Within the third replicate, SOCS3 protein levels were similar 
across all three cell lines (Figure 4.3c).  
Overall, based on average protein levels alone, SOCS3 expression showed little 
variation between the three cell lines. However, Ct values generated by qPCR demonstrated 
that modifications were sustained at the genetic level. Furthermore, all three cell lines 
maintained their expected phenotype throughout. SOCS3low cells proliferated rapidly, 





























Figure 4.3a. RPLPO and hSOCS3 mRNA were amplified by qPCR. Gene-specific amplification is 
demonstrated by the presence of two distinct melt peaks.   
Figure 4.3b. ΔCt values for SOCS3EV, SOCS3low and SOCS3high. ΔCt is defined as the difference 
between the cycle threshold value of SOCS3 and RPLP0 for each cell line. Relative SOCS3 expression 
was established by calculating the ΔCt of SOCS3low and SOCS3high as a proportion of SOCS3EV ΔCt.  
Figure 4.3c. Transgenic cells showed variation in SOCS3 protein levels despite sustaining genetic 
modifications. Cells from all three lines were lysed and the protein content was extracted and separated 
using SDS PAGE. Western blot was used to determine the abundance of SOCS3, as normalised against 
the housekeeping gene -actin. Three technical replicates were conducted within each biological replicate. 
Outliers greater than 2 standard deviations from the mean were excluded from statistical analysis.  N=8 






To investigate the potential link between SOCS3 and autophagy, beclin-1 and LC3B-I 
expression was assessed (Figure 4.4). Relative to empty vector controls, beclin-1 and LC3B-I 
were downregulated in both SOCS3low and SOCS3high cells (Figure 4.5). There was a mean 
decrease of 15.4% in beclin-1 expression by SOCS3low cells and a mean decrease of 39.1% in 
LC3B-I by SOCS3high cells. From these results, we can deduce that, relative to SOCS3EV 









Figure 4.4. Western blot analysis of autophagy markers in under-expressing (SOCS3low), normal 
(SOCS3EV) and overexpressing (SOCS3high) HIEC. Unstimulated HIEC cultures were lysed, then 
protein was extracted and separated by SDS PAGE. Western blot analysis was used to determine the 
abundance of beclin-1 and LC3B I in triplicate for each cell line, normalised against the housekeeping 















Finally, to investigate the effect of SOCS3 expression on the response of HIEC to 
cytosolic DNA, SOCS3low, SOCS3EV and SOCS3high HIEC were transfected with DNA as 
described in section 2.1.3. Activation of STAT3 and expression of STING was assessed using 
western blot analysis, as described in section 2.2. (Figure 4.6). The expression in SOCS3low 
and SOCS3high cells was calculated as percentage change from that in SOCS3EV controls 
(Figure 4.7). Although the data may illustrate modest increases in STAT3 and STING 
activation in cells both under-expressing and overexpressing SOCS3, the p values are non-
significant. Therefore, SOCS3 expression did not affect the response of HIEC to the presence 
of cytosolic DNA. 
 
Figure 4.5. Percentage change in beclin-1 and LC3B-I in untreated SOCS3low and SOCS3high cells, 
relative to SOCS3EV controls. Densitometry analysis was used to calculate normalised expression of 
beclin-1 and LC3B-I. The abundance of each protein was determined relative to -actin in each sample. 
Normalised protein expression cells both under-expressing and overexpressing SOCS3 was then 
expressed as percent change from that in empty vector controls. Outliers greater than 2 standard deviations 















Figure 4.6. Western blot analysis of pSTAT3, STAT3 and STING in under-expressing (SOCS3low), 
normally expressing (SOCS3EV) and over-expressing (SOCS3high) HIEC transfected with DNA. HIEC 
cultures which normally expressed, under-expressed and overexpressed SOCS3 were transfected with 
herring sperm DNA and lysed. Protein from the cell lysate was separated by SDS PAGE and used for 
western blot analysis of pSTAT3, STAT3 and STING signalling protein expression, normalised against 
the housekeeping gene -actin. This was repeated in triplicate for each cell line. 
Figure 4.7. Percentage change in the expression of activated STAT3 and STING in under-expressing 
(SOCS3low) and overexpressing (SOCS3high) cells, relative to empty vector controls (SOCS3EV) 
following transfection with DNA. Densitometry analysis was used to calculate normalised activation of 
STAT3 and expression of STING. The abundance of each protein was determined relative to -actin in each 
sample. Normalised protein expression cells both under-expressing and overexpressing SOCS3 was then 
expressed as percent change from that in empty vector controls. STAT3 activation by phosphorylation at 





5.1. Summary of Findings  
This thesis sought to investigate the effects of microbiome manipulation and SOCS3 
expression on cell signalling and autophagy in human intestinal epithelial cells and in 
functioning and defunctioned human intestine.  
In HIECs, DNA transfection was used as a model for viral infection and instigation of 
microbiome modulation, meanwhile SOCS3 expression was modulated using cell lines 
transfected with empty vector plasmids, SOCS3 expression plasmids and non-silencing shRNA 
lentiviral constructs. In human intestine, biopsies were taken from tissue adjacent to the site of 
loop ileostomy surgery which rendered it functional or defunctioned and thus harbouring a 
normal or depleted microbiota, respectively (Beamish et al., 2017). SDS PAGE, western blot 
and densitometry analysis were then used to quantify protein expression.  
 Whilst microbiome depletion affected autophagy in the human intestine, it did not 
impact SOCS3, STAT3 or STING signalling in human intestine or in HIECs. Furthermore, 
manipulation of SOCS3 was not found to impact STAT3 or STING signalling in HIECs but 
was again closely linked with autophagy. 
 
5.2. Clinical Relevance  
Loop ileostomy is a procedure used to protect intestinal anastomoses formed upon 
removal of a tumour from the colon and is usually reversed upon anastomotic healing, although 
some stoma formations are non-reversible due to complications and various patient morbidities 
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(Gessler et al., 2012, Chow et al., 2009). It is well known that the initial procedure renders the 
distal ileum defunctioned and atrophied (Winslet et al., 1991, Williams et al., 2007) however 
more recent research has suggested that despite this, there is no chronic inflammation in the 
defunctioned tissue based upon histological examination (Beamish et al., 2017). Furthermore, 
loss of function leads to decreased IEC proliferation and induces dysbiosis, with reductions in 
both bacterial load and diversity owed to nutrient deprivation (Beamish et al., 2017). 
 
5.3. Defunctioned Bowel Shows no Biochemical Signs of Inflammation 
Throughout the elucidation of the composition and function of the gut microbiome, our 
understanding of the virome – its viral component – remained poor. In fact, our acceptance of 
viruses as a component of a healthy microbiota is due to technological advances which have 
only recently made it possible to sequence these residents of the gut (Angly et al., 2005, Reyes 
et al., 2012). The virome is predominantly, but not exclusively, composed of bacteriophages 
which infect the bacteria of the microbiome and hence are heavily influential in the 
composition of the microbiota. In addition, viruses which infect both human cells and resident 
archaea are present.  
We have now obtained further evidence that the atrophied intestine is not chronically 
inflamed despite the occurrence of dysbiosis. Firstly, biochemical analysis of functioning and 
defunctioned tissue revealed that SOCS3, STAT3 and STING signalling pathways were not 
significantly impacted by DNA transfection by way of bowel defunction. Further non-
significant changes were observed during in vitro studies, in which microbiome modulation 




5.4. Autophagy is Implicated in Atrophy of the Defunctioned Bowel 
The histological analysis of functioning and defunctioned tissues conducted in this 
study supplemented the data collected by Beamish and colleagues (Beamish et al., 2017).  
Collaboratively, we observe villous atrophy in the defunctioned tissue, with a mean height 
reduction of 47% ±13.7. 
Loss of ileal function led to significant upregulation of autophagy, as indicated by 
beclin-1 expression. The nutrient-deprived ileum is subject to villous atrophy as well as loss of 
contractility and smooth muscle strength, which ultimately contribute to the complications 
experienced by many patients (Williams et al., 2007, Beamish et al., 2017).  
Upon diversion of the faecal stream, the distal ileal limb was deprived of enteral 
nutrition. Autophagy is a crucial process in sustaining cells placed under a range of stressors 
(Mizushima and Klionsky, 2007). It is likely that nutrient deprivation activated autophagy in 
the affected cells and recycled amino acids derived from the degraded proteins and organelles 
to obtain energy. In the short term, this mechanism allows cells to remain viable. However, to 
maintain tissue mass the rate of breakdown must equal the rate of synthesis. The tissues 
examined here were deprived of nutrition for prolonged periods and as such protein synthesis 
could not match its lysosomal degradation.  
In intestinal epithelial cells, such as those lining the crypts and villi, the most immediate 
response to nutrient deprivation is repression of cell growth and proliferation, as observed by 
Beamish et al. (Beamish et al., 2017). These processes require an energy surplus to proceed, 
but during prolonged periods of stress their termination is likely insufficient to retain cell 
viability and so lysosomal degradation of long-lived proteins and organelles may be 
upregulated. Reduced IEC proliferation to preserve energy, coupled with upregulated 
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autophagy to obtain it, creates an imbalance which favours atrophy of the intestinal epithelium, 
as seen by Williams and colleagues (Williams et al., 2007). 
Muscle tissue is the most abundant source of protein in the body. As well as numerous 
regulatory proteins found ubiquitously throughout eukaryotic cells, muscle cells harbour 
contractile proteins which generate the forces required to elicit contractions (Eddinger, 2014). 
In the case of smooth muscle within the intestine, these contractile forces are necessary to move 
the bolus through the gastrointestinal tract. Prolonged lysosomal degradation of protein 
comprising smooth muscle within the intestine will almost certainly have detrimental impacts 
to the function of the muscle, accounting for the well-documented loss of contractility and 
strength (Williams et al., 2007), as well as the marked increase in beclin-1 in defunctioned 
tissue observed in this study. 
 
5.5. The Link Between STING and SOCS3 Expression 
Whilst the results suggest a tendency for reduced STING activation in both transgenic 
cell lines in response to microbiome manipulation, the p value indicates that this is non-
significant. Upon closer investigation of the results, it is apparent that such a reduction is only 
observed in cells where SOCS3 protein levels have begun to fluctuate. Meanwhile in cells 
where SOCS3 protein is expressed as expected, there is a statistically significant upregulation 
of STING in cells both under- and overexpressing SOCS3, relative to empty vector controls.  
Overall, these data indicate that SOCS3 expression does not impact the cGAS-STING 
mediated response to cytosolic DNA. Within the first biological replicate, the relative increase 
in STING expression in both SOCS3high and SOCS3low cell lines was comparable in mean and 
range. Similarly, within the second and third biological replicates the relative decrease was 
near-identical in both measures. Whilst this indicates that SOCS3 under- and overexpression 
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does not impact STING signalling, it is worth noting that the apparent compensatory 
modulation of SOCS3 by the cells themselves coincides with the change from upregulation to 
downregulation of STING in both transgenic lines. It should therefore perhaps be considered 
that the mechanisms negating the changes to SOCS3 expression are also impeding the ability 
of these cells to activate STING in response to cytosolic DNA sensing. Meanwhile, in 
SOCS3EV cells, where no changes to SOCS3 expression were introduced, STING expression 
remained consistent.  
Whilst transgenic cells within the third biological replicate continued to underexpress 
STING relative to normal controls, beclin-1 expression became upregulated at this point. 
Upregulation of beclin-1 is an indicator of autophagy and has been linked with STING 
degradation (Liang et al., 2014). STING activation is required for the degradation of cytosolic 
DNA, however sustained activation would cause prolonged inflammation and have 
catastrophic effects on the host, meaning its termination is as important as its activation (Li et 
al., 2017). Both the activation and the subsequent repression of STING are dependent on the 
production of cyclic dinucleotides by cGAS. Initially, cGAS catalyses a reaction between GTP 
sand ATP to form the cyclic dinucleotide cGAMP, which binds and activates STING (Wu et 
al., 2013). However, once a sufficient response is elicited, cyclic dinucleotides also activate the 
Unc-51 like autophagy activating kinase 1 (ULK1), which represses STING via IRF3 (Konno 
et al., 2013). Additionally, beclin-1 interacts with cGAS to inhibit cGAMP production and 
STING activation. This interaction also releases the beclin-1 inhibitor Rubicon from its 
complex and induces beclin-1-mediated autophagy (Matsunaga et al., 2009, Liang et al., 2014). 







5.6.1. The Reliability of LC3B as a Measure of Autophagic Flux 
Under standard conditions, the LC3B protein, encoded by the MAP1LC3B gene is 
expressed and cleaved to form LC3B-I (He et al., 2003). During nutrient deprivation cytosolic 
LC3B-I is converted to the autophagosome membrane component LC3B-II (Tanida et al., 
2008). Although both forms are detectable by western blot, the use of LC3B as a measure of 
autophagic flux is controversial. On one hand, formation of LC3B-II is an unequivocal 
indication of autophagy induction as it directly corresponds with autophagosome formation. 
On the other hand, LC3B-II itself is degraded by autophagy, making its quantification an 
inaccurate reflection of autophagic flux (Mizushima and Yoshimori, 2007). With this limitation 
in mind, the optimal technique would be to measure LC3B-II levels in the presence and absence 
of lysosomal inhibitor, considering the difference to represent the protein utilised in 
autophagosome formation (Chittaranjan et al., 2015). Furthermore, LC3B-I and LC3B-II are 
often unequal in their affinity for the anti-LC3B antibody (Barth et al., 2010).  
It was apparent from the western blots (Figure 4.4.) that LC3B-I has a higher affinity 
for the antibody used in this instance, and so its abundance must be considered our most reliable 
indication of autophagic flux. Lacking a means of inhibiting lysosome formation, LC3B 
analysis is used simply to support or dispute the conclusions drawn upon analysis of beclin-1 
data. In HIEC, we associate high LC3B-I band density with lower rates of conversion to LC3B-
II, given the consistency in LC3B-II. We therefore negatively correlate LC3B-I and autophagy.  
Unfortunately, a similar approach could not be applied to the human intestine. The 
Bradford assay was used to calculate the crude total protein concentration in each tissue 
specimen, however this technique is prone to inter- and intra-assay variability (Rossi et al., 
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2015b). Furthermore, serial dilution of BSA was conducted to calibrate the assay and this is 
often associated with error propagation, resulting in inaccurate interpretation (Higgins et al., 
1998). In accordance with the concentrations calculated, 20μg of protein was used for SDS 
PAGE but western blot still revealed discrepancies in the protein concentration of different 
samples. As a result – and given its relatively low affinity for the antibody used – LC3B-II in 
human intestinal tissue was often undetectable and LC3B-I band density could not be used as 
a surrogate for conversion. 
 
5.6.2. The Impact of SOCS3 Regulation by Autophagy  
Western blot analysis revealed that within the first biological replicate, cells expressed 
the SOCS3 protein as expected. However, this appeared to be completely reversed in cells 
within the second biological replicate. By the time cells within the third biological replicate 
were harvested, SOCS3 protein levels were similar across all cells. However, all cell lines 
maintained the expected phenotypes throughout; SOCS3low cells rapidly proliferated, 
meanwhile the larger SOCS3high cells divided slowly. This phenotypic stability suggested that 
there had been no disruption to the changes made at the genetic level. Furthermore, the 
phenomenon of genetic compensation has been frequently reported in knockout cells but not 
in knockdowns, so it is unlikely that the transgenic cells produced would be capable of 
reversing the genetic modifications incurred (Tondeleir et al., 2012, Rossi et al., 2015b, Rossi 
et al., 2015a, Buglo et al., 2020). qPCR demonstrated that relative to empty vector controls, 
SOCS3 mRNA transcription was 30% lower and 55-fold greater in SOCS3low and SOCS3high 
cells, respectively. This confirmed that genetic compensation was not responsible for the 
changes observed and justified categorization of SOCS3 expression as ‘high’, ‘normal’ or ‘low’ 
based on functional characteristics, as opposed to protein levels. Afterall, SOCS3 is an 
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oscillatory protein and its expression is regulated in a number of ways (Yoshiura et al., 2007). 
In the intestinal epithelium, SOCS3 overexpression inhibits JAK/STAT signalling and is 
associated with IBD pathogenesis and relapse (Li et al., 2013). Meanwhile, under-expression 
facilitates hyperproliferation within intestinal crypts, causing inflammation and potentially 
tumour formation (Rigby et al., 2007). Furthermore, complete SOCS3 knockout causes 
embryonic lethality, reinstating the critical nature of its tight regulation (Roberts et al., 2001). 
With this in mind, it is unsurprising that transgenic cells should so stringently modulate the 
expression of this protein, despite changes at the genetic level.  
Given that the SOCS3 gene was transcribed as expected in all cell lines, it was logical 
to propose that degradation was occurring at the SOCS3 protein level. To investigate this 
possibility, the markers of autophagy beclin-1 and LC3B-I were analysed using western blot. 
In cells within the second and third biological replicates, there was a significant reduction in 
beclin-1 expression between SOCS3EV controls and SOCS3low cells, but no significant 
difference was observed between SOCS3EV and SOCS3high. Conversely, LC3B-I was 
significantly decreased in SOCS3high cells relative to SOCS3EV controls, but no significant 
difference was observed in SOCSlow cells. Relative to cells expressing SOCS3 normally, we 
observe decreased autophagy in under-expressing cells, and increased autophagy in over-
expressing cells. These findings are consistent with those of Koay and colleagues, who 
implicated autophagy in SOCS3 regulation (Koay et al., 2014).  
Although qPCR confirmed that transgenic cells maintained the correct genotype 
throughout, autophagy was regulating the abundance of the protein post-transcription. It should 
be considered that interactions involving the SOCS3 protein itself may be responsible for 




5.7. Future Direction  
Although the results indicate that activation of the cGAS-STING pathway is not 
impacted by SOCS3, the results are inconsistent. In the first biological replicate, STING 
activation was significantly elevated in both transgenic cell lines, relative to empty vector 
controls. Meanwhile, in the second and third replicates, significant reductions in STING 
activation were observed in all transgenic cells. The significance of these results implies that 
SOCS3 expression does impact activation of cGAS-STING upon detection of cytosolic DNA, 
but this impact remains undefined. The conflicting results should be addressed by conducting 
additional repeat experiments. Furthermore, additional read-outs including phosphorylation of 
STING or activation of downstream transcription factors should be tested using western Blot 
to quantify phospho-STING and IRF3, respectively. 
Our measurement of autophagic flux was limited by our inability to quantify the LC3B-
II used in autophagosome membrane synthesis. Further investigation, in which lysosomal 
degradation is inhibited, should be considered. However, given the statistical significance of 
the results obtained using beclin-1 as a measure of autophagic flux, this is not essential.  
Autophagy was found to regulate SOCS3 protein levels in transgenic cells. Therefore, 
potential interactions involving the protein itself, which cannot yet be considered, may be 
associated with modulating the response of transgenic cells to cytosolic DNA and should be 







5.8. Conclusion  
 Based on both histological and biochemical analysis, we have demonstrated that in our 
model, chronic inflammation is not always a consequence of dysbiosis. Rather, villous atrophy 
occurs and appears to be mediated by autophagy, which is likely important maintaining the 
dysbiotic environment.  
 Autophagy was downregulated in SOCS3low HIEC. Meanwhile, crude measurement of 
LC3B-I to LC3B-II conversion infers that the opposite is true when SOCS3 expression is 
increased, suggesting that SOCS3 may impact autophagy in the intestinal epithelium. Although 
this is true for our HIEC model of dysbiosis, it may not extend to the other cell types in the 
intestinal mucosa, as SOCS3 expression was unchanged in resection tissue.  
 SOCS3 is often silenced in tumours and upregulated in IBD (Lund and Rigby, 2006, Li 
et al., 2010). Overall, our results may suggest that SOCS3low cells, which may be considered a 
model for tumour cells, are less responsive to exogenous microbial stimuli and that SOCS3high 
cells, which may be considered a model for cells of the inflamed intestine are more responsive 
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6.1.  Supplementary Material for Chapter 3 
 
Tissue  STAT3 band density 
Functioning 0.0945 1.4369 0.4358 0.5791 0.0971 0.6665 0.5378 1.2278 6.4265 2.4836 0.9150 5.4016 1.0109 
Defunctioned 0.7504 0.7966 1.6332 1.3152 0.1707 0.3862 3.9112 0.6101 0.5199 0.9829 0.8792 2.0232 1.2936 
 
Tissue  STING band density 
Functioning 0.0090 0.0734 0.0696 0.2482 0.0010 0.9755 0.2544 0.0446 2.5668 0.0520 0.4273 1.3673 0.3315 
Defunctioned 0.1702 0.5432 1.4631 0.0040 0.3770 0.2629 0.1679 2.1771 1.2236 0.2654 1.1061 0.6604 1.1467 
 
 
Tissue  pSTAT3 band density 
Functioning 0.0110 1.9047 0.2051 0.4411 0.1709 0.3326 1.5101 0.9729 1.9349 1.3057 0.5330 2.9578 0.6630 
Defunctioned 0.2600 1.4784 6.5157 1.0996 0.2577 0.5418 5.2513 0.2865 0.1993 0.6228 0.5589 1.1754 0.9363 
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Tissue  SOCS3 band density 
Functioning 0.1024 7.2187 0.0341 0.6445 0.0772 1.0716 4.4775 0.1705 0.0734 0.6809 0.2835 2.7744 0.3192 
Defunctioned 0.1471 2.7726 2.3426 2.1897 0.0648 0.1638 9.2794 0.1267 0.0567 0.3266 0.2567 0.4260 0.3428 
 
Tissue  Beclin-1 band density 
Functioning  0.4509 1.6696 0.9165 0.9815 0.3009 0.9157 0.7224 0.3083 0.6767 0.2115 0.3481 2.4082 0.3132 




Band densities for pSTAT3, STAT3, STING and SOCS3 and beclin-1 tissue from defunctioned and functioning human intestine, normalised 





6.2. Supplementary Material for Chapter 4 
Treatment  pSTAT3 band density 
Control  1.0881 1.0842 0.8529 1.1538 0.7828 0.7584 0.7113 0.7412 1.0129 
K4 transfection 0.9559 0.8995 0.8617 0.8955 0.9437 0.9619 0.8375 0.9880 0.8889 
DNA stimulation 1.2683 1.1654 1.6075 0.7534 0.9890 0.7001 1.0074 0.6376 0.7855 
 
Treatment  STAT3 band density 
Control 1.2705 1.0366 1.1656 0.2687 1.4458 0.9849 0.6072 0.8572 1.1629 
K4 transfection 1.1020 1.0134 0.9238 0.9843 0.8992 1.0372 1.0981 1.0774 0.8721 
DNA stimulation 0.9936 0.9491 1.3606 1.1027 0.6196 0.6392 0.8738 0.7110 1.0982 
 
Treatment  STING band density 
Control 0.3328 0.2328 0.2529 1.1659 1.7792 1.0656 0.9892 0.9970 1.0620 
K4 transfection 0.3966 0.4122 0.6113 0.6514 1.2513 1.1329 1.4548 1.0000 1.0226 





Treatment  SOCS3 band density 
Control 0.8481 0.7184 0.7468 0.9444 1.5110 0.9114 0.7214 0.7330 0.9141 
K4 transfection 0.9348 0.9447 1.0294 1.1026 1.0448 1.1579 1.4118 1.1230 0.9223 




Band densities for pSTAT3, STAT3, STING and SOCS3 in untreated controls, cells transfected with K4 transfection reagent and DNA-








Cell line  SOCS3 band density 
SOCS3low 0.5879 0.5471 0.3963 1.7025 0.9198 0.7457 0.3453 0.5948 0.5314 
SOCS3EV 0.6389 0.6028 0.7497 0.4890 0.4395 0.5230 1.3067 1.3715 1.4336 











Cell line  Beclin-1 band density 
SOCS3low 0.8041 0.9511 0.8115 0.6064 0.5881 0.7604 
SOCS3EV 0.9140 1.0609 1.0116 0.6929 0.8169 0.8398 
SOCS3high 0.8811 1.1177 0.7150 0.6220 0.7763 0.4445 
 
Cell line LC3B-I band density  
SOCS3low 0.8241 1.0019 0.9038 0.3621 0.4846 0.7827 
SOCS3EV 0.9995 1.1837 0.9810 1.0550 1.1224 1.0505 










  Sum of Squares Degree of Freedom Mean Square F Significance  
Between cell lines  0.071 2 0.035 1.181 0.334 
Within cell lines  0.449 15 0.030     
Total 0.519 17       
 
Bonferroni 
Beclin1 Mean Difference Standard Error Significance 
95% Confidence Interval 
Lower Bound Upper Bound 
SOCS3 low SOCS3 EV -0.1357667 0.0998660 0.582 -0.404780 0.133246 
SOCS3 high -0.0058359 0.0998660 1.000 -0.274849 0.263177 
SOCS3 EV SOCS3 low 0.1357667 0.0998660 0.582 -0.133246 0.404780 
SOCS3 high 0.1299308 0.0998660 0.639 -0.139082 0.398944 
SOCS3 high SOCS3 low 0.0058359 0.0998660 1.000 -0.263177 0.274849 
SOCS3 EV  -0.1299308 0.0998660 0.639 -0.398944 0.139082 
 
Analysis of variance (ANOVA) and Bonferroni tests to compare the mean beclin-1 expression between and within untreated SOCS3low, 




  Sum of Squares Degree of Freedom Mean Square F Significance  
Between cell lines  0.705 2 0.353 9.999 0.002 
Within cell lines  0.529 15 0.035     
Total 1.235 17       
 
Bonferroni 
LC3B Mean Difference  Standard Error Significance 
95% Confidence Interval 
Lower Bound Upper Bound 
SOCS3 low SOCS3 EV -.3388341* 0.1084407 0.021 -0.630945 -0.046723 
SOCS3 high 0.1310235 0.1084407 0.737 -0.161088 0.423135 
SOCS3 EV SOCS3 low .3388341* 0.1084407 0.021 0.046723 0.630945 
SOCS3 high .4698576* 0.1084407 0.002 0.177746 0.761969 
SOCS3 high SOCS3 low -0.1310235 0.1084407 0.737 -0.423135 0.161088 
SOCS3 EV  -.4698576* 0.1084407 0.002 -0.761969 -0.177746 
*. The mean difference is significant at the 0.05 level. 
 
Analysis of variance (ANOVA) and Bonferroni tests to compare the mean LC3B-I expression between and within untreated SOCS3low, 
SOCS3EV and SOCS3high cell lines. 
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Cell line  PSTAT3 band density  
SOCS3low 1.0634 0.9891 1.1542 0.2972 0.3416 0.3978 0.8958 0.8301 0.9813 
SOCS3EV 1.0240 0.6818 0.7997 0.2431 0.2416 0.2456 0.9788 0.8817 0.9996 




Cell line  STAT3 band density  
SOCS3low 1.2377 1.0365 1.1244 0.3860 0.2651 0.4593 1.0373 1.0072 1.1269 
SOCS3EV 0.9159 1.0040 0.8667 0.3474 0.3135 0.3064 0.9089 0.9961 1.3317 
SOCS3high 0.7986 0.8996 1.0476 0.1072 0.1053 0.0791 0.8602 0.5638 0.9644 
Cell line  STING band density  
SOCS3low 0.9397 1.0250 0.8575 0.5958 0.5942 0.9666 0.8671 0.7277 0.9571 
SOCS3EV 0.4740 0.4707 0.5177 1.0044 1.0010 1.0327 1.0344 1.0509 1.1134 





Band densities for pSTAT3, STAT3 and STING in SOCS3low, SOCS3EV and SOCS3high cells stimulated with DNA, normalised against β actin. 























Analysis of variance (ANOVA) and Bonferroni tests to compare the mean STAT3 activation between and within DNA-stimulated SOCS3low, 
SOCS3EV and SOCS3high cell lines.  
ANOVA 
  Sum of Squares Degree of Freedom Mean Square F Significance  
Between cell lines  0.254 2 0.127 1.944 0.165 
Within cell lines  1.568 24 0.065     
Total 1.822 26       
Bonferroni 
Activated STAT3 Mean Difference Standard Error Significance 
95% Confidence Interval 
Lower Bound Upper Bound 
SOCS3 low SOCS3 EV 0.0687306 0.1204799 1.000 -0.241342 0.378803 
SOCS3 high -0.1625631 0.1204799 0.570 -0.472635 0.147509 
SOCS3 EV SOCS3 low -0.0687306 0.1204799 1.000 -0.378803 0.241342 
SOCS3 high -0.2312937 0.1204799 0.201 -0.541366 0.078778 
SOCS3 high SOCS3 low  0.1625631 0.1204799 0.570 -0.147509 0.472635 




  Sum of Squares Degree of Freedom Mean Square F Significance 
Between cell lines  0.003 2 0.001 0.032 0.968 
Within cell lines  1.056 24 0.044     
Total 1.059 26       
 
Bonferroni 
STING Mean Difference Standard Error Significance 
95% Confidence Interval 
Lower Bound Upper Bound 
SOCS3 low SOCS3 EV -0.0187165 0.0988830 1.000 -0.273206 0.235773 
SOCS3 high 0.0050522 0.0988830 1.000 -0.249437 0.259542 
SOCS3 EV SOCS3 low 0.0187165 0.0988830 1.000 -0.235773 0.273206 
SOCS3 high 0.0237687 0.0988830 1.000 -0.230721 0.278258 
SOCS3 high SOCS3 low -0.0050522 0.0988830 1.000 -0.259542 0.249437 
SOCS3 EV -0.0237687 0.0988830 1.000 -0.278258 0.230721 
 
Analysis of variance (ANOVA) and Bonferroni tests to compare the mean STING expression between and within DNA-stimulated SOCS3low, 
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